Tukysa (Tucatinib) is recommended for patients with metastatic HER2-positive breast cancer and RAS wild-type HER2-positive unresectable or metastatic colorectal cancer. Tucatinib is a tyrosine kinase inhibitor of HER2. In vivo, tucatinib inhibited the growth of HER2 expressing tumors. The combination of tucatinib and trastuzumab showed increased anti-tumor activity in vitro and in vivo compared to either drug alone.
What is Colorectal Cancer?
Colon (colorectal) cancer begins in your colon, the long tube that helps carry digested food to your rectum and out of your body.
Colon cancer develops from certain polyps or growths in the inner lining of the colon. Healthcare professionals have screening tests that detect precancerous polyps before they can become cancerous tumors. Colon cancer that’s not detected or treated may spread to other parts of the body. Fewer people are dying from colon cancer thanks to screening tests, early treatment, and new treatment.
Symptoms of Colorectal cancer
You can have colon cancer without having symptoms. If you have symptoms, you may not be sure if changes in your body are signs of colon cancer. That’s because some colon cancer symptoms are similar to symptoms of less serious conditions. Some of the symptoms are:
- Blood on or in your stool (poop)
- Persistent changes in your bowel habits
- Abdominal pain
- Bloated stomach
- Unexplained weight loss
Tukysa (Tucatinib) is a targeted (biological) therapy used by healthcare professionals in treating colorectal cancer in combination with trastuzumab and capecitabine. The recommended dosage of Tukysa 300 mg is taken twice a day orally in combination with trastuzumab until disease progression or unacceptable toxicity.
One can readily buy Tuksya in all major cities of India, and the price of Tuksya in India is economical. To know more about Tuksya, contact us at 18008891064 or firstname.lastname@example.org.